PDS Biotechnology Corporation - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PDSB Nasdaq 2830 www.pdsbiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PDS Biotechnology Corporation

Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - Jun 10th, 2026 7:55 am
PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... - May 13th, 2026 5:02 pm
PDS Biotechnology Q1 Earnings Call Highlights - May 13th, 2026 12:09 pm
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary - May 13th, 2026 10:52 am
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript - May 13th, 2026 6:26 am
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - May 13th, 2026 5:00 am
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results - May 6th, 2026 6:00 am
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial - Apr 15th, 2026 6:45 am
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Mar 31st, 2026 6:30 am
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ... - Mar 30th, 2026 7:01 pm
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - Mar 30th, 2026 5:00 am
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - Mar 24th, 2026 2:05 pm
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - Feb 20th, 2026 6:30 am
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - Jan 28th, 2026 6:45 am
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - Jan 22nd, 2026 6:45 am
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint - Jan 9th, 2026 6:45 am
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - Dec 9th, 2025 6:00 am
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - Dec 8th, 2025 10:00 am
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) - Dec 2nd, 2025 6:30 am
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Nov 26th, 2025 6:40 am